FR23C1035I2 - PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE IN TREATING PARKINSON'S DISEASE - Google Patents

PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE IN TREATING PARKINSON'S DISEASE

Info

Publication number: FR23C1035I2
Authority: FR; France
Prior art keywords: carbidopa; dopa; prodrugs; disease; treating parkinson
Prior art date: 2014-10-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1035C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AbbVie Inc

Original Assignee

AbbVie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-21

Filing date

2023-09-29

Publication date

2025-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1035(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2023-09-29 Application filed by AbbVie Inc filed Critical AbbVie Inc

2023-12-08 Publication of FR23C1035I1 publication Critical patent/FR23C1035I1/en

2025-04-18 Application granted granted Critical

2025-04-18 Publication of FR23C1035I2 publication Critical patent/FR23C1035I2/en

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

FR23C1035C 2014-10-21 2023-09-29 PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE IN TREATING PARKINSON'S DISEASE Active FR23C1035I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462066771P	2014-10-21	2014-10-21
PCT/US2015/056686 WO2016065019A1 (en)	2014-10-21	2015-10-21	Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number	Publication Date
FR23C1035I1 FR23C1035I1 (en)	2023-12-08
FR23C1035I2 true FR23C1035I2 (en)	2025-04-18

Family

ID=54478240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1035C Active FR23C1035I2 (en)	2014-10-21	2023-09-29	PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE IN TREATING PARKINSON'S DISEASE

Country Status (37)

Country	Link
US (7)	US9446059B2 (en)
EP (3)	EP4186510A1 (en)
JP (6)	JP6567049B2 (en)
KR (3)	KR20230066484A (en)
CN (4)	CN111454290B (en)
AR (1)	AR102389A1 (en)
AU (4)	AU2015335941B2 (en)
BR (1)	BR112017008198B1 (en)
CA (1)	CA2965379A1 (en)
CY (2)	CY1121826T1 (en)
DK (1)	DK3209302T3 (en)
ES (1)	ES2739536T3 (en)
FI (1)	FIC20230014I1 (en)
FR (1)	FR23C1035I2 (en)
HR (1)	HRP20191285T1 (en)
HU (2)	HUE044115T2 (en)
IL (3)	IL251829B (en)
LT (2)	LT3209302T (en)
LU (1)	LUC00304I2 (en)
MX (2)	MX393568B (en)
MY (1)	MY189519A (en)
NL (1)	NL301224I2 (en)
NO (1)	NO2023013I1 (en)
PH (1)	PH12017500746B1 (en)
PL (1)	PL3209302T3 (en)
PT (1)	PT3209302T (en)
RS (1)	RS58972B1 (en)
RU (2)	RU2021103000A (en)
SA (1)	SA521421115B1 (en)
SG (1)	SG11201703170RA (en)
SI (1)	SI3209302T1 (en)
SM (1)	SMT201900376T1 (en)
TR (1)	TR201908296T4 (en)
TW (2)	TWI755257B (en)
UA (1)	UA120437C2 (en)
WO (1)	WO2016065019A1 (en)
ZA (1)	ZA201702760B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
EP3777833B1 (en)	2014-03-13	2023-10-18	Neuroderm Ltd.	Dopa decarboxylase inhibitor compositions
CA2965379A1 (en)	2014-10-21	2016-04-28	Abbvie Inc.	Carbidopa and l-dopa prodrugs and methods of use
JP2019515908A (en) *	2016-04-20	2019-06-13	アッヴィ・インコーポレイテッド	Carbidopa and L-dopa prodrugs and methods of use
WO2017223182A1 (en) *	2016-06-22	2017-12-28	Medchem Partners, Llc.	Nitric oxide donors
WO2018154447A1 (en) *	2017-02-21	2018-08-30	Neuroderm Ltd	Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) *	2017-04-28	2018-11-01	Saniona A/S	Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en)	2017-11-16	2019-05-23	Orion Corporation	New use and pharmaceutical dosage forms
AR113908A1 (en)	2017-11-24	2020-06-24	H Lundbeck As	CATECOLAMINE PROPHARMACS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
CN110294789A (en) *	2018-03-21	2019-10-01	海南大学	The synthetic method of the oligopeptides containing DOPA and its application in terms of anti-Parkinson's disease prodrug
KR20210061355A (en)	2018-09-13	2021-05-27	유니버시티 오브 캔버라	Inhibition method
AU2019379806B2 (en)	2018-11-15	2025-08-14	Abbvie Inc.	Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) *	2019-03-04	2020-09-10	Neuroderm, Ltd.	Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11130775B2 (en)	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en)	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en)	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7696829B2 (en)	2019-05-21	2025-06-23	ハー・ルンドベック・アクチエゼルスカベット	Catecholamine carbamate prodrugs for use in the treatment of Parkinson's disease - Patents.com
US12384765B2 (en)	2019-05-21	2025-08-12	H. Lundbeck A/S	Catecholamine prodrugs for use in the treatment of Parkinson's Disease
WO2020234275A1 (en)	2019-05-21	2020-11-26	H. Lundbeck A/S	New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2020234276A1 (en)	2019-05-21	2020-11-26	H. Lundbeck A/S	New catecholamine prodrugs for use in the treatment of parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
EP4223288B1 (en)	2022-02-07	2024-03-06	Berlirem GmbH	Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3132171A (en) *	1962-06-18	1964-05-05	Strong Cobb Arner Inc	3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) *	1975-08-13	1977-04-05	Merck & Co., Inc.	Compositions and method of treating hypertension
DD230865B1 (en) *	1982-08-09	1987-05-20	Dresden Arzneimittel	PROCESS FOR THE PREPARATION OF HYDRAZINOCARBONSAEUREDERIVATES BY N-AMINATION OF AMINOCARBONSAEUREDERIVATES
US4508706A (en) *	1983-03-30	1985-04-02	Yale University	Composition for increasing melanin in mammalian skin and hair
US4618484A (en)	1983-03-30	1986-10-21	Yale University	Composition and method for treatment of melanomas
IT1213182B (en) *	1984-06-25	1989-12-14	Simes	DERIVATIVES OF COMPOUNDS WITH A CATECOLAMINICAL STRUCTURE.
US4616484A (en)	1984-11-30	1986-10-14	Kysor Industrial Corporation	Vehicle refrigerant heating and cooling system
IT1200427B (en)	1985-03-22	1989-01-18	Afros Spa	PROCESS AND PLANT FOR THE MOLDING OF PIECES IN EXPANDED PLASTIC MATERIAL, WITH SPRAY PREFORMED PARTS OR INSERTS IN THE SAME FORMING MOLD
JPH02138A (en)	1987-09-18	1990-01-05	Banyu Pharmaceut Co Ltd	L-dopa derivative
IT1226727B (en)	1988-07-29	1991-02-05	Simes	PRECURSOR DRUGS OF DOPAMIN.
ATE118216T1 (en) *	1989-04-20	1995-02-15	Zambon Spa	DOPAMINE MEDICINE PRECURSOR.
GB9102812D0 (en)	1991-02-11	1991-03-27	Enzymatix Ltd	Compounds
IT1255471B (en)	1992-07-30	1995-11-02	Zambon Spa	CATECOLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE9203594D0 (en)	1992-11-30	1992-11-30	Christer Nystroem	DISPERSA SYSTEM MEDICINAL PRODUCT
WO1999024442A1 (en) *	1997-11-12	1999-05-20	Ariad Pharmaceuticals, Inc.	Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en)	1998-01-20	2002-04-02	Glenn A. Meyer	Oral liquid compositions
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
KR20050016449A (en) *	2002-05-29	2005-02-21	임팩스 라보라토리즈, 인코포레이티드	Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003244088A1 (en)	2002-06-20	2004-01-06	Nippon Suisan Kaisha, Ltd.	Produrg, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en)	2002-12-06	2004-06-30	Xenoport, Inc.	Carbidopa prodrugs and uses thereof
WO2004069146A2 (en)	2003-02-07	2004-08-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	L-dopa amide derivatives and uses thereof
ATE495739T1 (en)	2003-08-29	2011-02-15	Transform Pharmaceuticals Inc	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING LEVODOPA AND CARBIDOPA
ES2360759T3 (en) *	2003-08-29	2011-06-08	Centocor Ortho Biotech Inc.	PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR USE OF LEVODOPA AND CARBIDOPA.
US20050163849A1 (en)	2003-10-31	2005-07-28	Wong Patrick S.	Compositions and dosage forms for enhanced absorption of iron
MX339690B (en)	2004-06-04	2016-06-06	Xenoport Inc	Levodopa prodrugs, and compositions and uses thereof.
EP2336138A3 (en)	2004-07-06	2011-11-16	Abbott Laboratories	Prodrugs of HIV protease inhibitors
RU2429223C2 (en) *	2005-12-05	2011-09-20	Ксенопорт, Инк.	Levodopa mesylate prodrug, composition thereof and use
CN101636145B (en) *	2006-05-31	2014-04-23	雅培产品有限公司	Long term 24 hour intestinal administration of levodopa/carbidopa
KR20090033871A (en) *	2006-06-16	2009-04-06	솔베이 파마슈티칼스 비. 브이	Combination Formulations Containing Bifeprunox and L-DOOPA
CA2673336A1 (en)	2006-12-21	2008-06-26	Xenoport, Inc.	Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en)	2007-07-06	2007-08-15	Proximagen Ltd	Amino acid derivatives
AU2009211028B2 (en) *	2008-02-06	2013-12-05	Wockhardt Research Centre	Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
BRPI0912326A2 (en)	2008-05-20	2015-10-06	Neurogesx Inc	water soluble acetaminophen analogs
US20130253056A1 (en)	2009-05-19	2013-09-26	Neuroderm, Ltd.	Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
EP3777839A1 (en)	2009-05-19	2021-02-17	Neuroderm Ltd	Compositions for continuous administration of dopa decarboxylase inhibitors
WO2011056240A2 (en)	2009-11-09	2011-05-12	Xenoport, Inc.	Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en)	2010-03-04	2015-01-20	University Of Notre Dame Du Lac	Gelatinase inhibitors and prodrugs
NZ610911A (en)	2010-11-15	2015-02-27	Neuroderm Ltd	Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
PH12013501117A1 (en)	2010-12-02	2013-07-22	Ono Pharmaceutical Co	Novel compound and medical use thereof
BR112013014304A2 (en)	2010-12-10	2016-07-19	Synagile Corp	subcutaneously infusible levodopa prodrug compositions and method of infusion
US8765189B2 (en)	2011-05-13	2014-07-01	Howmedica Osteonic Corp.	Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (en) *	2011-12-19	2013-06-27	울산대학교 산학협력단	Composition for prevention or treatment of neurodegenarative diseases
US20160022573A1 (en)	2013-03-13	2016-01-28	Neuroderm, Ltd.	Method for treatment of parkinson's disease
EP2994453A4 (en)	2013-03-15	2017-04-12	Techfields Pharma Co., Ltd.	Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
CA2965379A1 (en)	2014-10-21	2016-04-28	Abbvie Inc.	Carbidopa and l-dopa prodrugs and methods of use
MA41377A (en)	2015-01-20	2017-11-28	Abbvie Inc	LEVODOPA AND CARBIDONA INTESTINAL GEL AND PROCEDURES FOR USE
JP2019515908A (en)	2016-04-20	2019-06-13	アッヴィ・インコーポレイテッド	Carbidopa and L-dopa prodrugs and methods of use
EP3518920A1 (en)	2016-09-29	2019-08-07	Berlirem GmbH	L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en)	2017-02-21	2018-08-30	Neuroderm Ltd	Dopa decarboxylase inhibitor compositions

2015
- 2015-10-21 CA CA2965379A patent/CA2965379A1/en not_active Abandoned
- 2015-10-21 MX MX2021003840A patent/MX393568B/en unknown
- 2015-10-21 LT LTEP15791424.3T patent/LT3209302T/en unknown
- 2015-10-21 AU AU2015335941A patent/AU2015335941B2/en active Active
- 2015-10-21 EP EP22204022.2A patent/EP4186510A1/en active Pending
- 2015-10-21 SG SG11201703170RA patent/SG11201703170RA/en unknown
- 2015-10-21 KR KR1020237015051A patent/KR20230066484A/en not_active Ceased
- 2015-10-21 PL PL15791424T patent/PL3209302T3/en unknown
- 2015-10-21 ES ES15791424T patent/ES2739536T3/en active Active
- 2015-10-21 EP EP19164151.3A patent/EP3569587A1/en not_active Withdrawn
- 2015-10-21 HU HUE15791424 patent/HUE044115T2/en unknown
- 2015-10-21 TW TW110101738A patent/TWI755257B/en active
- 2015-10-21 JP JP2017521517A patent/JP6567049B2/en active Active
- 2015-10-21 RU RU2021103000A patent/RU2021103000A/en unknown
- 2015-10-21 AR ARP150103412A patent/AR102389A1/en unknown
- 2015-10-21 MY MYPI2017701367A patent/MY189519A/en unknown
- 2015-10-21 MX MX2017005236A patent/MX381069B/en unknown
- 2015-10-21 HR HRP20191285TT patent/HRP20191285T1/en unknown
- 2015-10-21 CN CN202010250046.4A patent/CN111454290B/en active Active
- 2015-10-21 KR KR1020247023761A patent/KR20240113982A/en active Pending
- 2015-10-21 WO PCT/US2015/056686 patent/WO2016065019A1/en not_active Ceased
- 2015-10-21 KR KR1020177013734A patent/KR102537018B1/en active Active
- 2015-10-21 TW TW104134601A patent/TWI718999B/en active
- 2015-10-21 TR TR2019/08296T patent/TR201908296T4/en unknown
- 2015-10-21 RU RU2017117413A patent/RU2743347C2/en active
- 2015-10-21 CN CN202010123543.8A patent/CN111362980B/en active Active
- 2015-10-21 BR BR112017008198-9A patent/BR112017008198B1/en active IP Right Grant
- 2015-10-21 CN CN201580069519.8A patent/CN107206013A/en active Pending
- 2015-10-21 SI SI201530761T patent/SI3209302T1/en unknown
- 2015-10-21 US US14/919,418 patent/US9446059B2/en active Active
- 2015-10-21 RS RS20190854A patent/RS58972B1/en unknown
- 2015-10-21 SM SM20190376T patent/SMT201900376T1/en unknown
- 2015-10-21 DK DK15791424.3T patent/DK3209302T3/en active
- 2015-10-21 PT PT15791424T patent/PT3209302T/en unknown
- 2015-10-21 EP EP15791424.3A patent/EP3209302B1/en active Active
- 2015-10-21 CN CN202010250040.7A patent/CN111494395B/en active Active
- 2015-10-21 UA UAA201704815A patent/UA120437C2/en unknown
2016
- 2016-07-21 US US15/216,009 patent/US20160362431A1/en not_active Abandoned
2017
- 2017-04-19 ZA ZA2017/02760A patent/ZA201702760B/en unknown
- 2017-04-20 IL IL251829A patent/IL251829B/en active IP Right Grant
- 2017-04-20 SA SA521421115A patent/SA521421115B1/en unknown
- 2017-04-21 PH PH12017500746A patent/PH12017500746B1/en unknown
- 2017-09-26 US US15/715,245 patent/US10174061B2/en active Active
2018
- 2018-12-05 US US16/210,996 patent/US10730895B2/en active Active
2019
- 2019-07-19 CY CY20191100771T patent/CY1121826T1/en unknown
- 2019-07-30 JP JP2019139442A patent/JP6750076B2/en active Active
- 2019-08-23 IL IL268885A patent/IL268885B/en active IP Right Grant
2020
- 2020-05-04 US US16/866,400 patent/US11091507B2/en not_active Expired - Fee Related
- 2020-08-04 IL IL276493A patent/IL276493A/en unknown
- 2020-08-11 JP JP2020135560A patent/JP6932227B2/en active Active
2021
- 2021-03-04 AU AU2021201414A patent/AU2021201414B2/en active Active
- 2021-07-16 US US17/378,321 patent/US20220153765A1/en not_active Abandoned
- 2021-08-16 JP JP2021132161A patent/JP2021183628A/en active Pending
2022
- 2022-10-24 US US17/971,836 patent/US20230106081A1/en not_active Abandoned
2023
- 2023-02-20 HU HUS2300009C patent/HUS2300009I1/en unknown
- 2023-03-07 CY CY2023010C patent/CY2023010I1/en unknown
- 2023-03-20 NO NO2023013C patent/NO2023013I1/en unknown
- 2023-03-24 NL NL301224C patent/NL301224I2/en unknown
- 2023-03-31 FI FIC20230014C patent/FIC20230014I1/en unknown
- 2023-04-03 LU LU00304C patent/LUC00304I2/fr unknown
- 2023-06-08 LT LTPA2023519C patent/LTC3209302I2/lt unknown
- 2023-08-04 AU AU2023210650A patent/AU2023210650A1/en not_active Abandoned
- 2023-09-29 FR FR23C1035C patent/FR23C1035I2/en active Active
- 2023-10-06 JP JP2023174083A patent/JP7688087B2/en active Active
2025
- 2025-05-21 JP JP2025084629A patent/JP2025118978A/en active Pending
- 2025-09-25 AU AU2025238004A patent/AU2025238004A1/en active Pending

Also Published As

Publication number	Publication date
NZ730996A (en)	2024-04-26
CN111362980A (en)	2020-07-03
AU2015335941B2 (en)	2021-04-01
RU2743347C2 (en)	2021-02-17
TR201908296T4 (en)	2019-06-21
TW202131931A (en)	2021-09-01
UA120437C2 (en)	2019-12-10
LUC00304I2 (en)	2025-09-22
CY1121826T1 (en)	2020-07-31
US20230106081A1 (en)	2023-04-06
FR23C1035I1 (en)	2023-12-08
CY2023010I2 (en)	2023-06-09
PT3209302T (en)	2019-07-19
SI3209302T1 (en)	2019-06-28
JP2023174770A (en)	2023-12-08
AR102389A1 (en)	2017-02-22
AU2021201414B2 (en)	2023-05-11
DK3209302T3 (en)	2019-05-13
NL301224I1 (en)	2023-03-29
MX381069B (en)	2025-03-12
JP2021183628A (en)	2021-12-02
EP3569587A1 (en)	2019-11-20
AU2023210650A1 (en)	2023-08-24
CA2965379A1 (en)	2016-04-28
PH12017500746A1 (en)	2017-10-30
BR112017008198A2 (en)	2017-12-26
PL3209302T3 (en)	2019-10-31
AU2015335941A1 (en)	2017-05-04
HUS2300009I1 (en)	2023-03-28
PH12017500746B1 (en)	2021-12-15
TWI718999B (en)	2021-02-21
NL301224I2 (en)	2023-08-16
JP7688087B2 (en)	2025-06-03
SA521421115B1 (en)	2022-03-01
US11091507B2 (en)	2021-08-17
JP6750076B2 (en)	2020-09-02
WO2016065019A1 (en)	2016-04-28
AU2025238004A1 (en)	2025-10-16
HRP20191285T1 (en)	2019-10-18
SG11201703170RA (en)	2017-05-30
RU2017117413A (en)	2018-11-26
US20220153765A1 (en)	2022-05-19
KR20170071599A (en)	2017-06-23
MX393568B (en)	2025-03-24
EP4186510A1 (en)	2023-05-31
CN111454290A (en)	2020-07-28
JP6567049B2 (en)	2019-08-28
US20190375770A1 (en)	2019-12-12
FIC20230014I1 (en)	2023-03-31
CN107206013A (en)	2017-09-26
KR20240113982A (en)	2024-07-23
SMT201900376T1 (en)	2019-09-09
IL268885B (en)	2020-08-31
IL251829B (en)	2019-09-26
HUE044115T2 (en)	2019-10-28
CN111362980B (en)	2022-10-18
IL268885A (en)	2019-10-31
RU2021103000A (en)	2021-03-01
ES2739536T3 (en)	2020-01-31
CN111454290B (en)	2022-12-23
NZ769153A (en)	2024-04-26
JP2020189864A (en)	2020-11-26
US20200262852A1 (en)	2020-08-20
TWI755257B (en)	2022-02-11
RS58972B1 (en)	2019-08-30
MX2021003840A (en)	2022-06-30
KR102537018B1 (en)	2023-05-30
MY189519A (en)	2022-02-16
IL251829A0 (en)	2017-06-29
JP2025118978A (en)	2025-08-13
LTC3209302I2 (en)	2025-10-10
CY2023010I1 (en)	2023-06-09
EP3209302A1 (en)	2017-08-30
US20160106765A1 (en)	2016-04-21
US10730895B2 (en)	2020-08-04
CN111494395A (en)	2020-08-07
IL276493A (en)	2020-09-30
US9446059B2 (en)	2016-09-20
TW201630924A (en)	2016-09-01
EP3209302B1 (en)	2019-04-24
LT3209302T (en)	2019-06-10
JP6932227B2 (en)	2021-09-08
KR20230066484A (en)	2023-05-15
JP2019218356A (en)	2019-12-26
AU2021201414A1 (en)	2021-03-25
US20160362431A1 (en)	2016-12-15
LTPA2023519I1 (en)	2023-06-26
CN111494395B (en)	2024-06-21
US20180079762A1 (en)	2018-03-22
ZA201702760B (en)	2022-05-25
RU2017117413A3 (en)	2019-05-30
JP2017537066A (en)	2017-12-14
BR112017008198B1 (en)	2021-02-09
MX2017005236A (en)	2017-07-26
US10174061B2 (en)	2019-01-08
NO2023013I1 (en)	2023-03-20

Publication	Publication Date	Title
FR23C1035I2 (en)	2025-04-18	PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE IN TREATING PARKINSON'S DISEASE
FR22C1011I2 (en)	2023-11-03	PRODRUGS OF FUMARATES AND THEIR USE FOR THE TREATMENT OF VARIOUS DISEASES
HUE051476T2 (en)	2021-03-01	Use of cannabidiol acid in the treatment of epilepsy
SI3240554T1 (en)	2019-12-31	Blautia stercosis and wexlerae for use in the treatment of inflammatory and autoimmune diseases
IL252943A0 (en)	2017-08-31	Sunitinib formulations and methods for use thereof in treatment of ocular disorders
MA41028A (en)	2017-10-03	METHODS AND FORMULATIONS FOR THE TREATMENT OF VASCULAR EYE PATHOLOGIES
HUE061761T2 (en)	2023-08-28	Tetrahydropyranyl-amino-pyrrolopyrimidinone for use in the treatment of BTK-mediated disorders
EP3307754A4 (en)	2019-03-27	COMPOSITIONS OF NICOTINAMIDE RIBOSIDE AND PTEROSTILBENE AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP3341391A4 (en)	2019-03-06	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
EP2978446A4 (en)	2016-08-31	METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP3376977A4 (en)	2019-07-10	RECOVERY AND TREATMENT OF TRAINED HUMAN EMBRYOS IN VIVO
HUE059387T2 (en)	2022-11-28	Treatment of Parkinson's disease
PT3302454T (en)	2021-04-01	Compositions for use in treating parkinson's disease and related disorders
PT3373922T (en)	2022-03-28	COMPOSITIONS AND METHODS TO USE IN THE TREATMENT OF HOMOCYSTINURIA
FR3030270B1 (en)	2018-03-16	COSMETIC TREATMENT PROCESS AND KIT THEREFOR
PL3727349T3 (en)	2025-02-10	NANOPARTICLES FOR USE IN TREATMENT OF NEURONAL DISORDERS
MD3364975T2 (en)	2021-09-30	Combination of trazodone and gabapentin for the treatment of pain
EP3344239A4 (en)	2019-05-22	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
PL3302463T3 (en)	2020-10-19	THE USE OF 3 DEOXYANTHYANIDINS IN THE TREATMENT OF EYE DISEASES
EP3322481A4 (en)	2019-03-06	TREATMENT OF DISEASES OF THE ROTATOR'S HAIR
FR3016881B1 (en)	2016-03-04	TREATMENT OF DEGENERESCENCES AND PHOTO-INDUCED LESIONS OF THE RETINA
EP2981324A4 (en)	2016-12-07	METHODS AND ARTICLES MANUFACTURED FOR THE TREATMENT OF SKIN
EP2825184A4 (en)	2015-12-30	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
EP3426803A4 (en)	2019-10-02	COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE
GB201504144D0 (en)	2015-04-22	Treatment of Parkinson's disease